Theravance Biopharma, Inc. - TBPH
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Apr 03, 2026 | SVP, COMM & MEDICAL AFFAIRS | A | A | 18,750.0 | 0.0 | 0.0 | 251,449.0 | View | |
| Apr 03, 2026 | SVP, GEN COUNSEL AND SECRETARY | A | A | 37,500.0 | 0.0 | 0.0 | 371,949.0 | View | |
| Apr 03, 2026 | SVP & CHIEF FINANCIAL OFFICER | A | A | 37,500.0 | 0.0 | 0.0 | 353,623.0 | View | |
| Apr 03, 2026 | CHIEF EXECUTIVE OFFICER | A | A | 75,000.0 | 0.0 | 0.0 | 1,651,094.0 | View | |
| Mar 18, 2026 | SVP, COMM & MEDICAL AFFAIRS | S | D | 7,766.0 | 13.9162 | 108,073.21 | 232,699.0 | View | |
| Mar 18, 2026 | SVP, COMM & MEDICAL AFFAIRS | S | D | 15,534.0 | 14.0 | 217,476.0 | 240,465.0 | View | |
| Mar 18, 2026 | SVP, COMM & MEDICAL AFFAIRS | S | D | 7,767.0 | 13.9163 | 108,087.9 | 255,999.0 | View | |
| Feb 24, 2026 | SVP, COMM & MEDICAL AFFAIRS | F | D | 13,929.0 | 19.66 | 273,844.14 | 263,766.0 | View | |
| Feb 24, 2026 | SVP, GEN COUNSEL AND SECRETARY | F | D | 20,833.0 | 19.66 | 409,576.78 | 334,449.0 | View | |
| Feb 24, 2026 | SVP, DEV & HEAD OF IRE OFFICE | F | D | 16,851.0 | 19.66 | 331,290.66 | 184,161.0 | View | |
| Feb 24, 2026 | SVP & CHIEF FINANCIAL OFFICER | F | D | 20,672.0 | 19.66 | 406,411.52 | 316,123.0 | View | |
| Feb 24, 2026 | CHIEF EXECUTIVE OFFICER | F | D | 74,975.0 | 19.66 | 1,474,008.5 | 1,576,094.0 | View | |
| Dec 05, 2025 | SVP, COMM & MEDICAL AFFAIRS | S | D | 15,534.0 | 18.7493 | 291,251.63 | 277,695.0 | View | |
| Dec 05, 2025 | SVP, COMM & MEDICAL AFFAIRS | S | D | 7,766.0 | 18.7508 | 145,618.71 | 293,229.0 | View | |
| Dec 05, 2025 | SVP, COMM & MEDICAL AFFAIRS | S | D | 7,767.0 | 18.7499 | 145,630.47 | 300,995.0 | View | |
| Dec 01, 2025 | — | M | A | 14,000.0 | 10.15 | 142,100.0 | 81,749.0 | View | |
| Dec 01, 2025 | — | S | D | 15,501.0 | 20.0 | 310,020.0 | 44,703.0 | View | |
| Dec 01, 2025 | — | S | D | 14,000.0 | 20.0 | 280,000.0 | 60,204.0 | View | |
| Nov 24, 2025 | SVP, COMM & MEDICAL AFFAIRS | F | D | 9,060.0 | 17.9 | 162,174.0 | 308,762.0 | View | |
| Nov 24, 2025 | SVP, GEN COUNSEL AND SECRETARY | F | D | 19,024.0 | 17.9 | 340,529.6 | 355,282.0 | View | |
| Nov 24, 2025 | SVP, DEV & HEAD OF IRE OFFICE | F | D | 6,989.0 | 17.9 | 125,103.1 | 201,012.0 | View | |
| Nov 24, 2025 | SVP & CHIEF FINANCIAL OFFICER | F | D | 18,627.0 | 17.9 | 333,423.3 | 336,795.0 | View | |
| Nov 21, 2025 | CHIEF EXECUTIVE OFFICER | F | D | 56,817.0 | 17.9 | 1,017,024.3 | 1,651,069.0 | View | |
| Nov 21, 2025 | CHIEF EXECUTIVE OFFICER | G | A | 9,900.0 | 0.0 | 0.0 | 23,400.0 | View | |
| Nov 21, 2025 | CHIEF EXECUTIVE OFFICER | G | D | 9,900.0 | 0.0 | 0.0 | 1,707,886.0 | View | |
| Nov 14, 2025 | — | M | A | 14,000.0 | 10.15 | 142,100.0 | 107,878.0 | View | |
| Nov 14, 2025 | — | S | D | 14,000.0 | 18.5 | 259,000.0 | 60,204.0 | View | |
| Nov 14, 2025 | — | S | D | 15,500.0 | 17.0 | 263,500.0 | 60,204.0 | View | |
| Nov 14, 2025 | — | S | D | 15,500.0 | 18.5 | 286,750.0 | 75,704.0 | View | |
| Nov 13, 2025 | — | M | A | 14,000.0 | 10.15 | 142,100.0 | 107,878.0 | View | |
| Nov 13, 2025 | — | S | D | 14,000.0 | 18.5 | 259,000.0 | 46,204.0 | View | |
| Nov 13, 2025 | — | S | D | 15,500.0 | 17.0 | 263,500.0 | 46,204.0 | View | |
| Nov 13, 2025 | — | S | D | 29,500.0 | 18.5 | 545,750.0 | 61,704.0 | View |